ABSTRACT
Hypertension (HTN) in children and adolescents is an important pathology, of, guarded prognosis, associated with modifiable and non-modifiable factors. The estimated prevalence is around 3.5% which increases progressively with age. The ideal method for its diagnosis is the measurement of blood pressure (BP) with auscultatory instruments. According to the American Academy of Pedia trics (AAP), BP should be measured in children older than three years of age once a year, and in children younger than three years of age if they present risk factors. Once the HTN is confirmed, the evaluation should be directed towards the detection of a causative disease and/or the search for risk factors associated with a primary HTN. The objective of treating primary and secondary HTN in pediatrics is to achieve a BP level that decreases the risk of target organ damage. Therapeutic op tions include treatment according to specific etiology, non-pharmacological and pharmacological one. This paper presents the position of the Chilean Society of Pediatrics Nephrology Branch with the aim of guiding pediatricians and pediatric nephrologists in the correct management of HTN in childhood. In this second part, recommendations on antihypertensive treatment are presented with an emphasis on lifestyle changes.
Subject(s)
Antihypertensive Agents/administration & dosage , Hypertension/therapy , Life Style , Adolescent , Age Factors , Blood Pressure/physiology , Blood Pressure Determination , Child , Child, Preschool , Chile , Humans , Hypertension/diagnosis , Practice Guidelines as Topic , Risk FactorsABSTRACT
Resumen: La hipertensión arterial (HTA) en niños y adolescentes es una importante patología, de reservado pronóstico, asociada a factores modificables y no modificables. La prevalencia estimada es de apro ximadamente un 3,5%, la cual va aumentando progresivamente con la edad. El método ideal para su diagnóstico es la medición de la presión arterial (PA) con instrumentos auscultatorios. De acuerdo a la Academia Americana de Pediatría (AAP) la PA debe ser medida en niños mayores de 3 años una vez al año, y en niños menores de 3 años, si presentan factores de riesgo. Una vez confirmada la HTA, la evaluación debe dirigirse hacia la detección de una enfermedad causal y/o a la búsqueda de factores de riesgo asociados a una HTA primaria. El objetivo del tratamiento de la HTA primaria y secundaria en pediatría es lograr un nivel de PA que disminuya el riesgo de daño de los órganos blanco. Las opciones terapéuticas incluyen: tratamiento según etiología específica, no farmacológico y farmacológico. En esta Guia se presenta la posición de la Rama de Nefrología de la Sociedad Chile na de Pediatría con el objetivo de orientar a pediatras y nefrólogos infantiles en correcto manejo de la HTA en la infancia. En esta segunda parte se presentan las recomendaciones sobre el tratamiento antihipertensivo, haciendo énfasis en los cambios de estilo de vida.
Abstract: Hypertension (HTN) in children and adolescents is an important pathology, of, guarded prognosis, associated with modifiable and non-modifiable factors. The estimated prevalence is around 3.5% which increases progressively with age. The ideal method for its diagnosis is the measurement of blood pressure (BP) with auscultatory instruments. According to the American Academy of Pedia trics (AAP), BP should be measured in children older than three years of age once a year, and in children younger than three years of age if they present risk factors. Once the HTN is confirmed, the evaluation should be directed towards the detection of a causative disease and/or the search for risk factors associated with a primary HTN. The objective of treating primary and secondary HTN in pediatrics is to achieve a BP level that decreases the risk of target organ damage. Therapeutic op tions include treatment according to specific etiology, non-pharmacological and pharmacological one. This paper presents the position of the Chilean Society of Pediatrics Nephrology Branch with the aim of guiding pediatricians and pediatric nephrologists in the correct management of HTN in childhood. In this second part, recommendations on antihypertensive treatment are presented with an emphasis on lifestyle changes.
Subject(s)
Humans , Child, Preschool , Child , Adolescent , Hypertension/therapy , Life Style , Antihypertensive Agents/administration & dosage , Blood Pressure/physiology , Blood Pressure Determination , Risk Factors , Age Factors , Practice Guidelines as Topic , Hypertension/diagnosisABSTRACT
Hypertension (HT) in children and adolescents is an important pathology, associated with modi fiable and non-modifiable factors. In the pediatric, the prevalence of HT is around 3.5%, and it in creases progressively with age. The ideal method for diagnosis is the measurement of blood pressure (BP) with auscultatory instruments. As published by the American Academy of Pediatrics (AAP), BP should be measured in children over 3 years of age once a year, and in children under 3 years of age, if it presents risk factors. Once HT has been confirmed, the evaluation should be directed towards the detection of a causative disease and the search for risk factors associated with primary HTN. The goal of treating primary and secondary HTN in pediatrics is to achieve a level of BP that decreases the risk of target organ damage. The therapeutic options include: treatment according to specific etiology, non-pharmacological and pharmacological. This document is the product of a collaborative effort of the Nephrology Branch of the Chilean Society of Pediatrics with the aim of helping pediatricians and pediatric nephrologists in the diagnosis and treatment of hypertension in childhood. In this first part, the recommendations of the diagnosis and study are presented.
Subject(s)
Hypertension/diagnosis , Hypertension/therapy , Adolescent , Antihypertensive Agents/therapeutic use , Blood Pressure Determination/methods , Child , Combined Modality Therapy , Humans , Hypertension/etiology , Medical History Taking , Physical Examination , Risk FactorsABSTRACT
Renal transplantation (RTx) is an effective therapy to improve clinical outcomes in pediatric patients with terminal chronic kidney disease. However, chronic immunosuppression with glucocorticoids (GCs) reduces bone growth and BMD. The mechanisms causing GC-induced growth impairment have not been fully clarified. Fibroblast growth factor 23 (FGF23) is a peptide hormone that regulates phosphate homeostasis and bone growth. In pathological conditions, FGF23 excess or abnormal FGF receptors (FGFR) activity leads to bone growth impairment. Experimental data indicate that FGF23 expression is induced by chronic GC exposure. Therefore, we hypothesize that GCs impair bone growth by increasing FGF23 expression, which has direct effects on bone growth plate. In a post hoc analysis of a multicentric randomized clinical trial of prepubertal RTx children treated with early GC withdrawal or chronic GC treatment, we observed that GC withdrawal was associated with improvement in longitudinal growth and BMD, and lower plasma FGF23 levels as compared with a chronic GC group. In prepubertal rats, GC-induced bone growth retardation correlated with increased plasma FGF23 and bone FGF23 expression. Additionally, GC treatment decreased FGFR1 expression whereas it increased FGFR3 expression in mouse tibia explants. The GC-induced bone growth impairment in tibiae explants was prevented by blockade of FGF23 receptors using either a pan-FGFR antagonist (PD173074), a C-terminal FGF23 peptide (FGF23180-205) which blocks the binding of FGF23 to the FGFR-Klotho complex or a specific FGFR3 antagonist (P3). Finally, local administration of PD173074 into the tibia growth plate ameliorated cartilage growth impairment in GC-treated rats. These results show that GC treatment partially reduces longitudinal bone growth via upregulation of FGF23 and FGFR3 expression, thus suggesting that the FGF23/Klotho/FGFR3 axis at the growth plate could be a potential therapeutic target for the management of GC-induced growth impairment in children.
Subject(s)
Bone Development/drug effects , Bone and Bones/metabolism , Fibroblast Growth Factors/metabolism , Glucocorticoids/administration & dosage , Kidney Transplantation , Receptor, Fibroblast Growth Factor, Type 3/metabolism , Signal Transduction/drug effects , Animals , Bone Density/drug effects , Bone and Bones/pathology , Child , Female , Fibroblast Growth Factor-23 , Follow-Up Studies , Glucocorticoids/adverse effects , Humans , Kidney Failure, Chronic/metabolism , Kidney Failure, Chronic/pathology , Kidney Failure, Chronic/surgery , Klotho Proteins , Male , Membrane Proteins , Mice , Rats , Rats, Sprague-DawleyABSTRACT
Resumen: La hipertensión arterial (HTA) en niños y adolescentes es una patología importante, asociada a fac tores modificables y no modificables. En la edad pediátrica, la prevalencia de la HTA es de alrededor de un 3,5%, y va aumentando progresivamente con la edad. El método ideal para su diagnóstico es la medición de la presión arterial (PA) con instrumentos auscultatorios. Según lo publicado por la Academia Americana de Pediatría (AAP) la PA debe ser medida en niños mayores de 3 años una vez al año, y en niños menores de 3 años, si presenta factores de riesgo. Una vez confirmada la HTA, la evaluación debe dirigirse hacia la detección de una enfermedad causal y a la búsqueda de factores de riesgo asociados a una HTA primaria. El objetivo del tratamiento de la HTA primaria y secundaria en pediatría es lograr un nivel de PA que disminuya el riesgo de daño de órgano blanco. Las opcio nes terapéuticas incluyen: tratamiento según etiología específica, no farmacológico y farmacológico. Este documento es producto de un esfuerzo colaborativo de la Rama de Nefrología de la Sociedad Chilena de Pediatría con el objetivo de ayudar a los pediatras y nefrólogos infantiles en el diagnóstico y tratamiento de la HTA en la infancia. En esta primera parte, se presentan las recomendaciones del diagnóstico y estudio.
Abstract: Hypertension (HT) in children and adolescents is an important pathology, associated with modi fiable and non-modifiable factors. In the pediatric, the prevalence of HT is around 3.5%, and it in creases progressively with age. The ideal method for diagnosis is the measurement of blood pressure (BP) with auscultatory instruments. As published by the American Academy of Pediatrics (AAP), BP should be measured in children over 3 years of age once a year, and in children under 3 years of age, if it presents risk factors. Once HT has been confirmed, the evaluation should be directed towards the detection of a causative disease and the search for risk factors associated with primary HTN. The goal of treating primary and secondary HTN in pediatrics is to achieve a level of BP that decreases the risk of target organ damage. The therapeutic options include: treatment according to specific etiology, non-pharmacological and pharmacological. This document is the product of a collaborative effort of the Nephrology Branch of the Chilean Society of Pediatrics with the aim of helping pediatricians and pediatric nephrologists in the diagnosis and treatment of hypertension in childhood. In this first part, the recommendations of the diagnosis and study are presented.
Subject(s)
Humans , Child , Adolescent , Hypertension/diagnosis , Hypertension/therapy , Physical Examination , Blood Pressure Determination/methods , Risk Factors , Combined Modality Therapy , Hypertension/etiology , Medical History Taking , Antihypertensive Agents/therapeutic useABSTRACT
[This corrects the article DOI: 10.1155/2013/970946.].
ABSTRACT
Growth failure is almost inextricably linked with chronic kidney disease (CKD) and end-stage renal disease (ESRD). Growth failure in CKD has been associated with both increased morbidity and mortality. Growth failure in the setting of kidney disease is multifactorial and is related to poor nutritional status as well as comorbidities, such as anemia, bone and mineral disorders, and alterations in hormonal responses, as well as to aspects of treatment such as steroid exposure. This review covers updated management of growth failure in these children including adequate nutrition, treatment of metabolic alterations, and early administration of recombinant human growth hormone (GH).
ABSTRACT
BACKGROUND: Glucocorticoid immunosuppressant therapy in pediatric kidney transplant (Tx) recipients does not allow the improvement of growth after Tx. OBJECTIVE: To determine the effect of early steroid withdrawal (SW) on longitudinal growth, insulin sensitivity (IS), and body composition (BC). METHODS: This was a prospective, randomized, multicenter study in Tx. Insulin-like growth factor (IGF)-I, IGF-binding protein 3 (IGFBP3), IS, and BC (DEXA/pQCT) were determined at baseline and up to 12 months after Tx. RESULTS: A total of 30 patients were examined; 14 patients were assigned to the SW group (7 male, 7 female; 12 in Tanner stage I) and 16 patients were assigned to the steroid control (SC) group (10 male, 6 female;12 in Tanner stage I). Their chronological age was 7.8 ± 4.3 years, height was -2.3 ± 0.99 SD scores (SDS), and body mass index -0.3 ± 1.2 SDS. After 1 year, the SW group showed an increase in height SDS (+1.2 ± 0.22 vs. +0.60 ± 0.13 SDS in the SC group, p < 0.02), lower IGFBP3 (p < 0.05), cholesterol (p < 0.05), and higher high-density lipoprotein cholesterol (p < 0.05). SW patients had lower trunk fat with no differences in IS. Only in prepubertal patients, the SW group had lower glycemia (p < 0.05), very low-density lipoprotein cholesterol (p < 0.01), triglycerides (p < 0.05), triglycerides/glycemia index (TyG; p < 0.02), and better lean mass. Both groups showed an improvement in lean mass after kidney Tx. CONCLUSIONS: SW improved longitudinal growth, lipid profile, and trunk and lean fat in Tx patients. In prepubertal recipients, the decrease in TyG suggests better IS.
Subject(s)
Adiposity , Body Height , Body Mass Index , Cholesterol/blood , Immunosuppressive Agents , Kidney Transplantation , Steroids , Child , Child, Preschool , Female , Humans , Insulin-Like Growth Factor Binding Protein 3/blood , Insulin-Like Growth Factor I/metabolism , Male , Prospective Studies , Time Factors , Transplantation, HomologousABSTRACT
This prospective, comparative trial investigated the impact on mean change in height standard deviation score (SDS), acute rejection rate, and renal function of early steroid withdrawal in 96 recipients with 5 years of follow-up. Recipients under basiliximab induction and steroid withdrawal (SW: TAC/MMF; n = 55) were compared with a matched steroid control group (SC: TAC/MMF/STEROID, n = 41). SW received steroids until Day 6, SC decreased to 10 mg/m(2) within 2 months post-transplant. Five years after SW, the longitudinal growth (SDS) gain was 1.4 ± 0.4 vs. 1.1 ± 0.3 for SC group (p < 0.02). Height benefits in prepubertal and pubertal status in both groups were demonstrated in the delta growth trends (mixed model; p < 0.01). Biopsy-proven acute rejection in SW was 11% and 17.5%, SC (p: ns). Mean eGFR (ml/min/1.73 m(2)) at 5 years post-transplant was SW 80.6 ± 27.8 vs. 82.6 ± 25.1 for SC (p: ns). The death-censored graft survival rate at 1 and 5 years was 99 and 90% for SW; 98 and 96% for SC (p = ns). PTLD incidence in SW 3.3 vs. 2.5% in SC (p: ns). Five years post-transplant, early steroid withdrawal showed positive impacts on growth, stable renal function without increased acute rejection risk, and PTLD incidence.
Subject(s)
Adrenal Cortex Hormones/administration & dosage , Body Height , Graft Rejection/epidemiology , Immunosuppressive Agents/administration & dosage , Kidney Transplantation , Adolescent , Antibodies, Monoclonal/administration & dosage , Basiliximab , Body Height/drug effects , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Male , Recombinant Fusion Proteins/administration & dosageABSTRACT
Tradicionalmente se evitaba arriesgar un transplante renal en niños con mal funcionamiento de su vía urinaria. Nuestro centro fue pionero en la región en promover el concepto que la ampliación vesical permitiría un transplante renal exitoso. Para evaluar la veracidad de aquel concepto, revisamos todos aquellos niños tranplantados renales (TX) que tuvieron ampliación vesical (AV). Método: Se realizó revisión retrospectiva de fichas clínicas e imágenes radiológicas de todos los pacientes del programa de transplante renal de nuestro hospital en los últimos 22 años. Los criterios de inclusión fueron haber sido transplantado y haber sido operado de AV previo al 31 de diciembre de 2005. Resultados: Entre 1983- 2005 se realizaron 93 TX. De los 80 casos en que se recuperó todos los datos, 16 (20 por ciento) niños recibieron AV; 7 niñas y 9 niños. Edad y peso promedio al momento del TX fue 12 años (rango 6-17a) y 26 kilos (rango 14-41kg) respectivamente. Los diagnósticos urológicos eran vejiga neurogénica (n =8), uropatía obstructiva (n =5) y RVU (n =3). El segmento utilizado para AV fue ureter (n =7), sigmoide sin desmucosar (n =5), sigmoide desmucosado (n =2) e ileon (n =2). 5 pacientes fueron ampliados post TX. Después de un tiempo promedio de seguimiento de 71 meses (rango 12-144m), las complicaciones más frecuentes fueron ITU (n =13), RVU (n =6), litiasis (n =2) y acidosis metabólica (n =1). Se pudo recuperar información urodinamica previo a la ampliación vesical en 9/16 niños y post ampliación en 16/16. La capacidad vesical pre y post- ampliación presentó una mediana de 108 cc (rango 20-250 cc) y 450cc (rango 130-800cc) respectivamente. La acomodación previo a la AV estaba disminuida en 9/9 (<10 ml/cmH2O) y fue buena en 16/16 (>25 ml/cmH2O). La creatinina post-cirugía en promedio era de 1,28 mg/dl (rango 0,4- 2,39 mg/dl). No hubo pérdida del injerto en esta serie, siendo comparable la sobrevida a 5 años con aquellos niños trasplantados sin ampliación...
The traditional thought was that to relate a kidney transplant (KT) and a bladder augmentation (BA) could be risky. Our centre was one of the first in the region to promote the concept that a bladder augmentation would allow a successful KT. The aim of this study is to evaluate the veracity of that concept. Methods: Case note review of all the patients of the Kidney Transplant Programme from our hospital in the last 22 years. Inclusion criteria were to have received a KT and also a BA before december 31st 2005. Results: There were 93 KT between 1983 and 2005. From the 80 cases where data could be recovered, 16(20 percent) had a BA; 7 girls and 9 boys. Age and weight at the transplant time was 12 years (range 6-17 y) and 26 kg (range 14-41 kg) respectively. Urological diagnoses were neurogenic bladder (n =8), obstructive uropathy (n =5) and VUR (n =3). The segment used for BA was ureter (n =7), sigmoid without demucosalized(n =5), demucosalized sigmoid (n =2) and ileum (n =2). 5 patients were augmented after KT. The mean follow-up was 71 months (range 12-144m) and the most frequent complications were UTI (n =13), VUR (n=6), lithiasis (n=2) and metabolic acidosis (n =1). Pre transplant urodynamic data could be recovered in 9/16 cases and post KD in 16/16. Median bladder capacity pre and post transplantation was 108 cc (range 20-250cc) and 450cc (range 130-800cc) respectively. Bladder compliance pre transplant was reduce in 9/9 (<10 ml/cmH2O) and was good in 16/16 (>25 ml/cmH2O). The mean post KT creatinine was1.28 mg/dl (range 0.4-2.39 mg/dl). There was no graft lost in this series, presenting comparable graft survival at 5 years with those cases of KT without BA. Conclusión: Considering that graft survival is similar between those children with and without bladder augmentation, the authors confirm that BA is not a risky procedure for a KT. On the other hand, if 20 percent of the patient of our Kidney Transplant Programme required...
